Compugen (CGEN) Given a $9.00 Price Target at Oppenheimer

Oppenheimer set a $9.00 target price on Compugen (NASDAQ:CGEN) in a report issued on Wednesday morning. The firm currently has a buy rating on the biotechnology company’s stock.

Separately, Zacks Investment Research upgraded shares of Compugen from a hold rating to a buy rating and set a $4.00 price target for the company in a research report on Tuesday, October 16th.

NASDAQ CGEN traded down $0.15 on Wednesday, hitting $3.37. The company’s stock had a trading volume of 9,684 shares, compared to its average volume of 401,565. Compugen has a 1-year low of $2.25 and a 1-year high of $5.00. The stock has a market cap of $157.98 million, a P/E ratio of -4.75 and a beta of 1.32.

Compugen (NASDAQ:CGEN) last announced its quarterly earnings results on Wednesday, November 7th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.12) by $0.07. The business had revenue of $7.80 million during the quarter, compared to analyst estimates of $7.80 million. On average, analysts expect that Compugen will post -0.42 EPS for the current year.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Commonwealth Equity Services LLC acquired a new stake in shares of Compugen during the second quarter worth $106,000. Aviance Capital Management LLC acquired a new stake in shares of Compugen during the third quarter worth $151,000. Benjamin F. Edwards & Company Inc. increased its position in shares of Compugen by 34.4% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 167,600 shares of the biotechnology company’s stock worth $553,000 after buying an additional 42,900 shares during the period. Taylor Frigon Capital Management LLC increased its position in shares of Compugen by 24.3% during the second quarter. Taylor Frigon Capital Management LLC now owns 666,302 shares of the biotechnology company’s stock worth $2,199,000 after buying an additional 130,217 shares during the period. Finally, UBS Group AG increased its position in shares of Compugen by 1,813.2% during the first quarter. UBS Group AG now owns 316,066 shares of the biotechnology company’s stock worth $1,406,000 after buying an additional 299,546 shares during the period. Institutional investors own 20.69% of the company’s stock.

Compugen Company Profile

Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations.

Featured Story: Put Option

Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply